<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04514367</url>
  </required_header>
  <id_info>
    <org_study_id>ANX005-HD-01</org_study_id>
    <nct_id>NCT04514367</nct_id>
  </id_info>
  <brief_title>An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease</brief_title>
  <official_title>A Phase 2a Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Annexon, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Annexon, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multi-center, open-label study of intravenous (IV) ANX005 in subjects with,&#xD;
      or at risk for, manifest Huntington's Disease (HD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to evaluate the effects of intravenous ANX005 administered for&#xD;
      up to 22 weeks in subjects with, or at risk for, manifest Huntington's Disease.&#xD;
&#xD;
      Subjects will receive induction dosing of ANX005 administered by IV infusion on Days 1 and 5&#xD;
      or 6, followed by maintenance dosing every 2 weeks through Week 22, with follow up visits on&#xD;
      Weeks 24, 28, and 36.&#xD;
&#xD;
      All subjects will be contacted (in clinic visit or phone call) 6 months after study&#xD;
      completion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 17, 2020</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>ANX005 administered for up to 22 weeks</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events (Safety and Tolerability) of ANX005</measure>
    <time_frame>Up to Week 36</time_frame>
    <description>As measured by incidence of TEAEs, SAEs, AEs related to ANX005, SAEs related to ANX005, Grade 3 or higher AEs, Grade 3 or higher AEs related to ANX005, AEs leading to study or treatment discontinuation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of ANX005</measure>
    <time_frame>Up to Week 36</time_frame>
    <description>As measured by ANX005 serum and cerebrospinal fluid concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD) effects of ANX005</measure>
    <time_frame>Up to Week 36</time_frame>
    <description>As measured by C1q, C4a, and NfL blood and/or cerebrospinal fluid concentrations</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Huntington Disease</condition>
  <arm_group>
    <arm_group_label>ANX005</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ANX005</intervention_name>
    <description>Intravenous Infusion</description>
    <arm_group_label>ANX005</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of or at risk for Huntington's disease: Genetically confirmed disease by&#xD;
             direct DNA testing, total CAG-Age Product (CAP) score &gt; 400 and UHDRS independence&#xD;
             score ≥ 80.&#xD;
&#xD;
          2. Able to walk independently and self-sufficient in basic activities of daily living&#xD;
             (e.g. eating, dressing, bathing).&#xD;
&#xD;
          3. All HD concomitant medications stable.&#xD;
&#xD;
          4. If female, must be postmenopausal (no menses for at least 2 years without an&#xD;
             alternative medical cause), surgically sterilized (bilateral tubal ligation, bilateral&#xD;
             oophorectomy, or hysterectomy), or agree to use highly effective methods of&#xD;
             contraception.&#xD;
&#xD;
          5. Males with a woman of childbearing potential partner must agree to use highly&#xD;
             effective methods of contraception.&#xD;
&#xD;
          6. Previously vaccinated against encapsulated bacterial pathogens (Neisseria&#xD;
             meningitidis, Haemophilus influenzae, and Streptococcus pneumoniae) or willing to&#xD;
             undergo vaccination.&#xD;
&#xD;
          7. Able to tolerate EEG and lumbar puncture (LP) procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Be at risk of suicide or self-harm within the preceding 12 months.&#xD;
&#xD;
          2. Chorea and/or cognitive deficits severe enough to interfere with study assessments.&#xD;
&#xD;
          3. Subjects with body weight &gt; 150 kg.&#xD;
&#xD;
          4. Clinically significant findings on the screening laboratory testing or physical&#xD;
             examination that are not specific to HD and may interfere with the conduct of the&#xD;
             study or the interpretation of the data or increase subject risk.&#xD;
&#xD;
          5. Signs and symptoms of, or a diagnosis consistent with a chronic autoimmune disorder&#xD;
             and/or an ANA titer ≥ 1:160.&#xD;
&#xD;
          6. History of previous infusion reactions, sensitivities, allergic, or anaphylactic&#xD;
             reactions to previous medications, environmental stimuli or other substances.&#xD;
&#xD;
          7. Use of an experimental agent within 60 days or five half-lives prior to Screening or&#xD;
             anytime over the duration of this study.&#xD;
&#xD;
          8. Prior treatment with any monoclonal antibody.&#xD;
&#xD;
          9. Presence of an implanted deep brain stimulation device.&#xD;
&#xD;
         10. Any history of gene therapy, RNA or DNA targeted HD specific investigational agents&#xD;
             such as antisense oligonucleotides, cell transplantation or any experimental brain&#xD;
             surgery.&#xD;
&#xD;
         11. Brain and spinal pathology that may interfere with cerebrospinal fluid homeostasis and&#xD;
             circulation, increases intracranial pressure (implanted shunt or catheter),&#xD;
             malformations or tumor.&#xD;
&#xD;
         12. Contraindication to undergoing an LP.&#xD;
&#xD;
         13. Hypersensitivity to any of the excipients in the ANX005 drug product.&#xD;
&#xD;
         14. Clinically significant intercurrent illness, medical condition, or medical history&#xD;
             (including neurological or mental illness, HIV, any active infection, including&#xD;
             Hepatitis B or C) that would jeopardize the safety of the subject, limit&#xD;
             participation, or compromise the interpretation of the data derived from the subject.&#xD;
&#xD;
         15. Any known genetic deficiencies of the complement-cascade system.&#xD;
&#xD;
         16. History of chronic oral or intravenous steroid use or immunosuppressant medication&#xD;
             use.&#xD;
&#xD;
         17. Hemoglobin, bilirubin, or lactate dehydrogenase (LDH) values that are outside normal&#xD;
             limits and clinically significant or suggestive of hemolytic anemia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajeev Kumar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rocky Mountain Movement Disorders Center, Englewood, CO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Annexon Investigational Site 02</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Annexon Investigational Site 03</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Annexon Investigational Site 04</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Annexon Investigational Site 07</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Annexon Investigational Site 06</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Annexon Investigational Site 08</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 27, 2020</study_first_submitted>
  <study_first_submitted_qc>August 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2020</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

